التفاصيل البيبلوغرافية
| العنوان: |
Feasibility of home dose optimization of apomorphine sublingual film in Parkinson’s disease patients with OFF episodes: results from the dose-optimization phase of an open-label, randomized crossover study |
| المؤلفون: |
Kassubek, Jan, Stocchi, Fabrizio, Martinez, Ernest Balaguer, Pahwa, Rajesh, Ondo, William, Zhang, Yi, Bowling, Alyssa, Pappert, Eric, Isaacson, Stuart, Wu, Stacy |
| المساهمون: |
BIAL–Portela & Cª, S.A, Sunovion Pharmaceuticals Inc. |
| المصدر: |
Therapeutic Advances in Neurological Disorders ; volume 16 ; ISSN 1756-2864 1756-2864 |
| بيانات النشر: |
SAGE Publications |
| سنة النشر: |
2023 |
| مصطلحات موضوعية: |
Neurology (clinical), Neurology, Pharmacology |
| الوصف: |
Background: Dose optimization of sublingual apomorphine (SL-APO), a dopamine agonist for the treatment of OFF episodes in patients with Parkinson’s disease (PD), has been performed under clinical supervision in clinical trials. SL-APO may be a candidate for home dosing optimization which would be less burdensome for patients. Objectives: To evaluate the feasibility and safety of home optimization of SL-APO in patients with PD and OFF episodes. Design: A multicenter, randomized, crossover study comparing SL-APO with subcutaneous apomorphine was conducted, comprising an open-label dose-optimization phase and a treatment phase. This non-comparative analysis focuses on the outcomes of the dose-optimization phase with SL-APO only. Methods: Patients with PD and OFF episodes received SL-APO at an initial dose of 10 mg in the clinic (open-label). Further optimization could continue at home in 5 mg increments during subsequent OFF episodes (maximum dose of 30 mg). Optimization and tolerability were assessed daily by patient-reported feedback via telephone. Patients reporting a FULL ON returned to the clinic for a dose-confirmation visit (DCV). In patients with inadequate response as determined during the DCV, the dose could be further optimized at home. Results: Home optimization was continued by 81.4% (83/102) of patients. Of these, 80.7% identified an effective, tolerable dose. Mean time between initial clinic visit and DCV 1 was 6.8 days, and the final optimized dose of SL-APO was 30 mg (mode). In total, 62.7% of patients reported ⩾1 adverse event; the most common included nausea (31.4%), dizziness (9.8%), somnolence (8.8%), dyskinesia (7.8%), and fatigue (5.9%). The safety profile in this study in which most patients performed home dose optimization was consistent with the study utilizing clinic-based optimization. Conclusion: After the first clinic dose, home dose optimization of SL-APO appears feasible in patients with PD and OFF episodes, with most patients identifying their optimal SL-APO dose at home. Trial ... |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| DOI: |
10.1177/17562864231209240 |
| الإتاحة: |
https://doi.org/10.1177/17562864231209240Test |
| حقوق: |
https://creativecommons.org/licenses/by-nc/4.0Test/ |
| رقم الانضمام: |
edsbas.1640CBC4 |
| قاعدة البيانات: |
BASE |
